VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Govindan on the Future of EGFR-Mutant NSCLC

Ramaswamy Govindan, MD
Published: Thursday, May 11, 2017



Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Clinical practice is already changing, Govindan says, as physicians are biopsying patients at the time of disease progression and obtaining cell-free DNA analyses. Moreover, second-line therapy is being decided based on gene alterations.

Secondly, Govindan explains that there is a good strategy in place for at least half of the patients who progress beyond the first-generation EGFR inhibitor. In the coming years, investigators will find a way to combine various agents and, hopefully, come up with novel agents that move downstream to work alongside EGFR inhibitors, as well. 
 


Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Clinical practice is already changing, Govindan says, as physicians are biopsying patients at the time of disease progression and obtaining cell-free DNA analyses. Moreover, second-line therapy is being decided based on gene alterations.

Secondly, Govindan explains that there is a good strategy in place for at least half of the patients who progress beyond the first-generation EGFR inhibitor. In the coming years, investigators will find a way to combine various agents and, hopefully, come up with novel agents that move downstream to work alongside EGFR inhibitors, as well. 
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x